Feasibility Study of Using Molecular Fluorescence Guided Surgery in Endometriosis
NCT ID: NCT02975219
Last Updated: 2017-06-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1
10 participants
INTERVENTIONAL
2017-05-01
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ICG-Based Fluorescence Imaging for Intra-operative Detection of Endometriosis
NCT03017989
The Role of FAPI PET-CT in Diagnosing Endometriosis
NCT06792318
Efficacy of Cryoablation of Abdominal Wall Endometriosis
NCT03627676
The (Cost-)Effectiveness of Surgical Excision of Colorectal Endometriosis Compared to ART Treatment Trajectory
NCT05677269
Evaluation of Endometriosis With 18F-fluoroestradiol PET / MRI
NCT04382911
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment group
4.5mg Bevacizumab-800CW intravenously
Bevacizumab-800CW
4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab-800CW
4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Scheduled for surgery for the treatment of endometriosis
3. WHO performance score of 0-2
4. Written informed consent
For female subjects who are of childbearing potential, are premenopausal with intact reproductive organs or are less than 2 years post-menopausal:
5. A negative serum pregnancy test prior to receiving the tracer
6. Willing to ensure that she or her partner uses effective contraception during the trial and for 6 months thereafter.
Exclusion Criteria
2. Pregnancy
3. History of infusion reactions to Bevacizumab or other monoclonal antibody therapies
4. Significant renal, cardiac, or pulmonary disease (ASA III-IV)
18 Years
99 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Medical Center Groningen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
G.M. van Dam
prof. dr.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gooitzen van Dam, prof dr
Role: PRINCIPAL_INVESTIGATOR
UMCG
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Medical Center Groningen
Groningen, , Netherlands
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2016/304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.